- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07573839
An Exploratory Study on the Prediction of Recurrence Risk of Bipolar Disorder Using Sentiment Analysis Technology Based on Multi-modal Feature Fusion
1. mai 2026 oppdatert av: Jun CHEN, Shanghai Mental Health Center
Bipolar disorder (BD) has become a significant public health problem with complex clinical manifestations, difficult treatment, and poor prognosis.
However, there is still a lack of effective biological markers for diagnosing and predicting recurrence.
Sentiment analysis computing usually refers to using machine equipment to classify, identify, interpret, and imitate human emotions.
However, current multi-modal emotion analysis research is mainly based on one or two modalities.
Due to the diversity and complexity of patients' emotional expressions, this single- and dual-modal information analysis is far from enough for accurate discrimination of emotional symptoms.
Only emotion analysis technology based on multi-modal feature fusion can make more precise and effective judgments.
The current project is based on our previous research on cognitive neuroimaging and big data analysis of bipolar disorder.
The investigators plan to enroll 200 BD patients who meet DSM-5 diagnostic criteria and 200 healthy controls.
The investigators will use sentiment analysis technology with multi-modal feature fusion (text data, audio and visual modalities, eye movements, and electrophysiology) to identify BD recurrence.
Biological markers for risk prediction and an algorithm model for joint judgment of multi-source information will be established to analyze the characterization data.
The effectiveness of this recurrence prediction model will be further verified and optimized through a large-sample, prospective cohort study design.
It is hoped that it can provide a new method for predicting the recurrence risk of BD patients.
In the near future, clinical decision-making aids based on this auxiliary method can be developed, and the translational application value of clinical diagnosis and treatment can be explored.
Studieoversikt
Status
Rekruttering
Forhold
Intervensjon / Behandling
Studietype
Observasjonsmessig
Registrering (Antatt)
400
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Shanghai, Kina
- Rekruttering
- Shanghai Mental Health Center
-
Ta kontakt med:
- Jun CHEN
- Telefonnummer: 021-34773523
- E-post: doctorcj2010@gmail.com
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
Tar imot friske frivillige
Ja
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
1. patients with bipolar disorder; 2. healthy controls.
Beskrivelse
Patients group inclusion criteria:
- Patients who have previously met or currently meet the diagnostic criteria for bipolar disorder according to DSM-5, whose condition and treatment are currently stable, and who cooperate with the assessment;
- Age ≥18 years, <65 years;
- Han Chinese ethnicity;
- Sufficient visual and auditory abilities to complete the necessary examinations for the study;
- Understanding the study content and signing the informed consent form. If the patient is unable to sign the informed consent form personally due to low education level or other reasons, it may be signed by a relative or guardian on their behalf.
exclusion criteria:
- The presence of intellectual disability or other conditions that significantly affect the patient's current mental state;
- the patient has a serious or unstable physical illness, including: neurological disorders (delirium, dementia, stroke, epilepsy, migraine, etc.), congestive heart failure, angina pectoris, myocardial infarction, arrhythmia, hypertension (including untreated or uncontrolled hypertension), malignant tumors, immunodeficiency, and blood glucose levels higher than 12 mmol/L; or other diseases that may interfere with the test assessment (abnormal indicators more than twice the normal value).
Healthy controls group inclusion criteria:
- Age ≥ 18 years, < 65 years;
- Han Chinese ethnicity;
- Gender matched to the patient group;
- Sufficient visual and auditory ability to complete the necessary examinations for the study;
- Understanding of the study content and signing of informed consent;
- No family history of mental illness. exclusion criteria:
- Individuals with a mental disorder conforming to DSM-5, or those with suspicious mental symptoms but not meeting the diagnostic criteria;
- Individuals with severe physical illness that makes it difficult to complete the necessary examinations.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
sunn kontroll
|
This is an observational study with no intervention.
|
|
patients with bipolar disorder
|
This is an observational study with no intervention.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The recurrence status of patients with bipolar disorder
Tidsramme: 1 year, patients will be followed-up every 3 months and healthy controls will be assessed only at baseline
|
The presence and the type of a relapse will be diagnosed by psychiatrists and assessed using DSM-5 by study assistants.
Furthermore, predictive models for recurrence risk of bipolar disorder will be constructed, with adopting the Area Under Curve (AUC) of Receiver Operating Characteristic (ROC) and other measurements to evaluate the performance of constructed models.
|
1 year, patients will be followed-up every 3 months and healthy controls will be assessed only at baseline
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Antatt)
1. april 2026
Primær fullføring (Antatt)
1. desember 2027
Studiet fullført (Antatt)
1. desember 2027
Datoer for studieregistrering
Først innsendt
13. april 2026
Først innsendt som oppfylte QC-kriteriene
1. mai 2026
Først lagt ut (Faktiske)
7. mai 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
7. mai 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
1. mai 2026
Sist bekreftet
1. mai 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 8247054596
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .